Publicaciones en las que colabora con FRANCISCO JAVIER DOLCET ROCA (10)

2020

  1. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma

    Journal of Investigative Dermatology, Vol. 140, Núm. 6, pp. 1253-1265

2016

  1. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels

    Pigment Cell and Melanoma Research, Vol. 29, Núm. 3, pp. 352-371

2012

  1. Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

    Molecular Oncology, Vol. 6, Núm. 5, pp. 530-541

  2. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway

    International Journal of Cancer, Vol. 130, Núm. 4, pp. 967-978

2009

  1. Expression of somatostatin receptors in human melanoma cell lines: Effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation

    Journal of International Medical Research, Vol. 37, Núm. 6, pp. 1813-1822

2008

  1. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells

    Anti-Cancer Drugs, Vol. 19, Núm. 2, pp. 115-124

  2. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines

    British Journal of Dermatology, Vol. 158, Núm. 3, pp. 496-504

  3. Targeted therapies in gynecologic cancers and melanoma

    Seminars in Diagnostic Pathology, Vol. 25, Núm. 4, pp. 262-273

2007

  1. Nuevas dianas terapéuticas en el melanoma

    Piel, Vol. 22, Núm. 4, pp. 205-211

2006

  1. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines

    Melanoma Research, Vol. 16, Núm. 2, pp. 127-135